Brought to you by 
StrideBio gets $15.7mm via Series A
04 Jun 2019
Executive Summary
StrideBio Inc. (developing novel adeno-associated viral (AAV) vectors for in vivo gene therapies aimed at rare diseases) raised $15.7mm in an oversubscribed Series A financing led by Hatteras Venture Partners, which was joined by Takeda Ventures, UCB Ventures, and Alexandria Venture Investments. A representative from Takeda Ventures and UCB Ventures will join the board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
StrideBio gets $15.7mm via Series A
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice